New Leaf has received approval from Health Canada to allow its wholly-owned subsidiary Psirenity to begin construction of a psilocybin research facility at its Norfolk County location.
The Controlled Drug and Substances Act licensed facility will be focused on psilocybin and psilocin production, as well as strain development, extraction, and the formulation of investigational products for future clinical trials. The facility will also supply the drugs needed for Psirenity’s Health and Wellness Therapy Clinic.
Chris McCullough, CEO of Psirenity, said the company is expected to begin construction on the new facility within the next 60 days.
“It will establish a real footprint in Canada for Psirenity’s psilocybin and psilocin research once we receive CDSA licensing approval from Health Canada. Our work will hopefully lead to vital, new treatments in psychedelic-enhanced mental health, allowing Psirenity to commit itself even further to developing its unique Science of Peace of Mind,” said McCullough.